NCT06141031 2026-03-17
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1 Active not recruiting
Clinical Trials
22 trialsNCT05488522 2026-02-20
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT07075120 2025-10-28
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Not yet recruiting
NCT06130826 2025-05-30
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT02643498 2024-12-20
A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03802747 2024-12-09
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Phase 1 Withdrawn
NCT03716596 2024-09-20
CISPD-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Terminated
NCT06558175 2024-08-16
REPAIR
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1 Not yet recruiting
NCT05088889 2023-11-28
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
Sheba Medical Center
Phase 1 Unknown
NCT01068327 2023-10-10
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 1 Completed
NCT01918644 2022-06-01
Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
University of Wisconsin, Madison
Phase 1 Completed
NCT02507765 2021-10-13
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT02707328 2019-07-30
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
The Cooper Health System
Phase 1 Terminated
NCT01739439 2019-07-29
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Fox Chase Cancer Center
Phase 1 Terminated
NCT02868632 2019-04-05
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NYU Langone Health
Phase 1 Withdrawn
NCT02298946 2019-02-22
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01025882 2019-02-05
Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1 Terminated
NCT02611661 2018-08-16
LASER
Washington University School of Medicine
Phase 1 Terminated
NCT01446458 2016-03-22
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Emory University
Phase 1 Completed
NCT01801163 2015-04-16
A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Indiana University
Phase 1 Withdrawn
NCT00230347 2010-04-01
Evaluation of Stereotactic Radiosurgery For Liver Malignancies
Stanford University
Phase 1 Completed